Comparative Analysis: Resistance of Klebsiella Pneumoniae to Fluoroquinolone and Carbapenem in European Countries

References

[1] Holt, K. E., Wertheim, H., Zadoks, R. N., Baker, S., Whitehouse, C. A., Dance, D., ... & Thomson, N. R. (2015). Genomic analysis of diversity, population structure, virulence, and antimicrobial resistance in Klebsiella pneumoniae, an urgent threat to public health. Proceedings of the National Academy of Sciences, 112(27), E3574-E3581.

[2] Rydberg, J., Larsson, C., & Miörner, H. (1994). Resistance to fluoroquinolones in Pseudomonas aeruginosa and Klebsiella pneumoniae. Scandinavian journal of infectious diseases, 26(3), 317-320.

[3] Shahraki, S., Mohammadzadeh-Rostami, F., Haddadi-Feishani, M., Mohagheghifard, A. H., Jahani, S., & Majidiani, H. (2015). Evaluation of quinolone-resistant strains of Klebsiella pneumoniae in clinical specimens obtained from patients referred to Zahedan educational hospitals. Zahedan Journal of Research in Medical Sciences, 17(8).

[4] Dalhoff, A. (2012). Global fluoroquinolone resistance epidemiology and implications for clinical use. Interdisciplinary perspectives on infectious diseases, 2012(1), 976273.

[5] Gavriliu, L. C., Benea, O. E., & Benea, S. (2016). Antimicrobial resistance temporal trend of Klebsiella pneumoniae isolated from blood. Journal of Medicine and Life, 9(4), 419m

[6] Kitchel, B., Rasheed, J. K., Patel, J. B., Srinivasan, A., Navon-Venezia, S., Carmeli, Y., ... & Giske, C. G. (2009). Molecular epidemiology of KPC-producing Klebsiella pneumoniae isolates in the United States: clonal expansion of multilocus sequence type 258. Antimicrobial agents and chemotherapy, 53(8), 3365-3370

[7] Hussein, K., Sprecher, H., Mashiach, T., Oren, I., Kassis, I., & Finkelstein, R. (2009). Carbapenem resistance among Klebsiella pneumoniae isolates risk factors, molecular characteristics, and susceptibility patterns. Infection Control & Hospital Epidemiology, 30(7), 666-671

[8] Candan, E., & Aksöz, N. (2015). Klebsiella pneumoniae: characteristics of carbapenem resistance and virulence factors. Acta Biochimica Polonica, 62(4), 867-874.

[9] Moradigaravand, D., Martin, V., Peacock, S. J., & Parkhill, J. (2017). Evolution and epidemiology of multidrug-resistant Klebsiella pneumoniae in the United Kingdom and Ireland. MBio, 8(1), 10-1128.

[10] Amereh, F., Arabestani, M. R., & Shokoohizadeh, L. (2023). Relationship of OqxAB efflux pump to antibiotic resistance, mainly fluoroquinolones in Klebsiella pneumoniae, isolated from hospitalized patients. Iranian Journal of Basic Medical Sciences, 26(1), 93.

[11] Collins, J. A., Oviatt, A. A., Chan, P. F., & Osheroff, N. (2024). Target-mediated fluoroquinolone resistance in Neisseria gonorrhoeae: actions of ciprofloxacin against gyrase and topoisomerase IV. ACS infectious diseases, 10(4), 1351-1360.

[12] Liang, H., Zhang, J., Hu, J., Li, X., & Li, B. (2023). Fluoroquinolone residues in the environment rapidly induce heritable fluoroquinolone resistance in Escherichia coli. Environmental Science & Technology, 57(12), 4784-4795.

[13] Scroggs, S., Gass, J.,Chinnasamy, R.,Widen, S., Azar, S.,Rossi,S, Arterburn, J.,Vasilakis, N., Hanley, K., (2021). Evolution of resistance to fluoroquinolones by dengue virus serotype 4 provides insight into mechanism of action and consequences for viral fitness. Virology 552, 94-106,

[14] Sorlozano, A., Gutierrez, J., Jimenez, A., de Dios Luna, J., & Martínez, J. L. (2007). Contribution of a new mutation in parE to quinolone resistance in extended-spectrum-β-lactamase-producing Escherichia coli isolates. Journal of clinical microbiology, 45(8), 2740-2742.

[15] Vila, J., Ruiz, J., Marco, F., Barcelo, A., Goni, P., Giralt, E., & Jimenez de Anta, T. (1994). Association between double mutation in gyrA gene of ciprofloxacin-resistant clinical isolates of Escherichia coli and MICs. Antimicrobial agents and chemotherapy, 38(10), 2477-2479.

@article{1709911,
      author = {Olufunmilayo A. Mohammed, Peter Uaboi-Egbenni, Perezimor Etifa},
      title = {Comparative Analysis: Resistance of Klebsiella Pneumoniae to Fluoroquinolone and Carbapenem in European Countries},
      journal = {Iconic Research And Engineering Journals},
      year = {2025},
      volume = {9},
      number = {1},
      pages = {1852-1857},
      issn = {2456-8880},
      url = {https://www.irejournals.com/formatedpaper/1709911.pdf},
      abstract = {K. pneumonia has been reported as a threat to human health due to the emergence of multidrug resistant isolates. This research was aimed at identifying the resistance rates of K. Pneumoniae to fluoroquinolones in 2021, its European age distribution and its resistance rates compared to carbapenems. The potential for K. Pneumoniae to increase or reduce susceptibility  to fluoroquinolones in the next decade was determined by examining the resistance profile in 4 European countries for 16 years. Results observed highlighted that K. Pneumoniae isolates in Europe were more susceptible to Carbapenems compared to fluoroquinolones in the year 2021. The research also identified an  over 50% resistance of  K. Pneumoniae Europeans isolate for ages 19 and higher. The about 2 fold resistance increase observed to fluoroquinolones over16 years pose a high therapeutic threat to Europeans over the age of 19 over the next decade as K. Pneumoniae has shown tendencies to increase in their resistance rates. Thus European Health organisations need to create policies to curb the use of fluoroquinolones in the treatment of K. Pneumoniae infections and preserve administration to rare cases to limit rate of resistance development.},
      month = {July},
  }